GlassScriptPhysician profile
Robert A Weisberg
NPI 1639116650
$800.79
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $219 · 2021: $196 · 2022: $92.61.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $197.78 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $168.79 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $152.80 | 2019-2022 | |
| Glaxosmithkline, LLC. | $55.79 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.70 | 2021 | |
| Abbvie INC. | $51.64 | 2021 | |
| Sunovion Pharmaceuticals INC. | $40.32 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $19.74 | 2022 | |
| Amarin Pharma, INC. | $19.02 | 2020 | |
| Alkermes, INC. | $13.96 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.90 | 2019 | |
| Gilead Sciences, INC. | $12.35 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Weisberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.